[Featured Stock] HLB Surges on News of Passing FDA Clinical Trial Inspection for Liver Cancer Drug
HLB is showing strong performance.
As of 9:47 AM on the 18th, HLB was trading at 78,800 won, up 16,500 won (26.48%) from the previous trading day.
HLB's liver cancer drug candidate, Rivoceranib, has passed the clinical trial site inspection, a hurdle it had previously failed. This is being seen as a green light for its challenge for approval in the United States.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
On the 18th, HLB announced that it received a "No Action Indicated (NAI)" rating in the FDA's Bioresearch Monitoring Inspection (BIMO). NAI means "passed."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.